Literature DB >> 21991270

Broadening the concept of bipolar disorder: what should be done in the face of uncertainty?

Mark Zimmerman1.   

Abstract

Entities:  

Year:  2011        PMID： 21991270      PMCID： PMC3188765          DOI： 10.1002/j.2051-5545.2011.tb00048.x

Source DB:  PubMed          Journal:  World Psychiatry        ISSN： 1723-8617            Impact factor:   49.548


× No keyword cloud information.
  10 in total

1.  Issues for DSM-V: unintended consequences of small changes: the case of paraphilias.

Authors:  Michael B First; Allen Frances
Journal:  Am J Psychiatry       Date:  2008-10       Impact factor: 18.112

2.  Is 4 days the minimum duration of hypomania in bipolar II disorder?

Authors:  F Benazzi
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2001       Impact factor: 5.270

3.  Heterogeneity of DSM-IV major depressive disorder as a consequence of subthreshold bipolarity.

Authors:  Petra Zimmermann; Tanja Brückl; Agnes Nocon; Hildegard Pfister; Roselind Lieb; Hans-Ulrich Wittchen; Florian Holsboer; Jules Angst
Journal:  Arch Gen Psychiatry       Date:  2009-12

4.  Misdiagnosed patients with bipolar disorder: comorbidities, treatment patterns, and direct treatment costs.

Authors:  Louis S Matza; Krithika S Rajagopalan; Christine L Thompson; Gregory de Lissovoy
Journal:  J Clin Psychiatry       Date:  2005-11       Impact factor: 4.384

5.  Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study.

Authors:  S N Ghaemi; E E Boiman; F K Goodwin
Journal:  J Clin Psychiatry       Date:  2000-10       Impact factor: 4.384

6.  Psychiatrists' and nonpsychiatrist physicians' reported use of the DSM-IV criteria for major depressive disorder.

Authors:  Mark Zimmerman; Janine Galione
Journal:  J Clin Psychiatry       Date:  2010-01-26       Impact factor: 4.384

7.  Economic consequences of not recognizing bipolar disorder patients: a cross-sectional descriptive analysis.

Authors:  Howard G Birnbaum; Lizheng Shi; Ellison Dial; Emily F Oster; Paul E Greenberg; David A Mallett
Journal:  J Clin Psychiatry       Date:  2003-10       Impact factor: 4.384

Review 8.  Borderline or bipolar? Distinguishing borderline personality disorder from bipolar spectrum disorders.

Authors:  Joel Paris
Journal:  Harv Rev Psychiatry       Date:  2004 May-Jun       Impact factor: 3.732

9.  Is bipolar disorder overdiagnosed?

Authors:  Mark Zimmerman; Camilo J Ruggero; Iwona Chelminski; Diane Young
Journal:  J Clin Psychiatry       Date:  2008-06       Impact factor: 4.384

10.  Toward a re-definition of subthreshold bipolarity: epidemiology and proposed criteria for bipolar-II, minor bipolar disorders and hypomania.

Authors:  Jules Angst; Alex Gamma; Franco Benazzi; Vladeta Ajdacic; Dominique Eich; Wulf Rössler
Journal:  J Affect Disord       Date:  2003-01       Impact factor: 4.839
  10 in total
  4 in total

1.  WPA contribution to the development of the chapter on mental disorders of the ICD-11.

Authors: 
Journal:  World Psychiatry       Date:  2012-06       Impact factor: 49.548

Review 2.  DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences—part 2: bipolar disorders, schizophrenia spectrum disorders, anxiety disorders, obsessive-compulsive disorders, trauma- and stressor-related disorders, personality disorders, substance-related and addictive disorders, neurocognitive disorders.

Authors:  Hans-Jürgen Möller; Borwin Bandelow; Michael Bauer; Harald Hampel; Sabine C Herpertz; Michael Soyka; Utako B Barnikol; Simone Lista; Emanuel Severus; Wolfgang Maier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-08-26       Impact factor: 5.270

3.  WPA contribution to the development of the chapter on mental disorders of the ICD-11: An update.

Authors:  Umberto Volpe
Journal:  World Psychiatry       Date:  2013-06       Impact factor: 49.548

4.  WPA partnership with the World Health Organization in the development of the ICD-11 chapter on mental disorders.

Authors:  Paola Bucci
Journal:  World Psychiatry       Date:  2013-02       Impact factor: 49.548
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.